<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4652497</article-id><article-id pub-id-type="publisher-id">2051-1426-3-S2-P435</article-id><article-id pub-id-type="doi">10.1186/2051-1426-3-S2-P435</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Sanborn</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Boulmay</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Li</surname><given-names>Rui</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Spieler</surname><given-names>Bradley</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Happel</surname><given-names>Kyle</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Paustian</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Mougdil</surname><given-names>Tarsem</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Feng</surname><given-names>Zipei</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Dubay</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Fisher</surname><given-names>Brenda</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Koguchi</surname><given-names>Yoshinobu</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Aung</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Mederos</surname><given-names>Eileen</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Bifulco</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>McNamara</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A16"><name><surname>Bahjat</surname><given-names>Keith S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A17"><name><surname>Redmond</surname><given-names>William</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A18"><name><surname>Ochoa</surname><given-names>Augusto C</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A19"><name><surname>Hu</surname><given-names>Hong Ming</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A20"><name><surname>Fox</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A21"><name><surname>Urba</surname><given-names>Walter</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" corresp="yes" id="A22"><name><surname>Hilton</surname><given-names>Traci</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib></contrib-group><aff id="I1"><label>1</label>Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA</aff><aff id="I2"><label>2</label>Stanley S. Scott Cancer Center, School of Medicine, LSUHSC, New Orleans, LA, New Orleans, LA, USA</aff><aff id="I3"><label>3</label>Providence Cancer Center, Portland, OR, USA</aff><aff id="I4"><label>4</label>Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA</aff><aff id="I5"><label>5</label>Earle A. Chiles Research Institute, Portland, OR, USA</aff><aff id="I6"><label>6</label>Prometheus Laboratories Inc., San Diego, CA, USA</aff><aff id="I7"><label>7</label>UbiVac, Portland, OR, USA</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>4</day><month>11</month><year>2015</year></pub-date><volume>3</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by SITC 2015.</named-content></supplement><fpage>P435</fpage><lpage>P435</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Sanborn et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Sanborn et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/3/S2/P435"/><conference><conf-date>4-8 November 2015</conf-date><conf-name>30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</conf-name><conf-loc>National Harbor, MD, USA</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>Tumor-derived autophagosomes, DRibbles, are DC-targeted microvesicles containing more than 100 putative NSCLC antigens, many as potential altered-peptide ligands (APL), which could increase their immunogenicity. The microvesicles also contain at least 15 DAMPs with agonist activity for TLR 2, 3, 4, 7 and 9. In preclinical models DRibble immunotherapy provided significant cross-protection against 8 of 9 tumors and was effective in treating established tumors. We hypothesize that the efficacy of DRibbles' vaccination stems from their ability to present stabilized tumor-derived short-lived proteins (SLiPs) and defective ribosomal products (DRiPs) that are normally not processed and presented by professional antigen presenting cells (APCs). These SLiPs and DRiPs represent a potential pool of tumor antigens against which the host is not tolerant. The DPV-001 vaccine is made up of DRibbles produced from two cell lines, UbiLT3 and UbiLT6. The priming vaccination includes DRibbles from both cell lines, while subsequent administrations alternate between DRibbles derived from the two cell lines.</p></sec><sec><title>Methods and results</title><p>Patients are vaccinated at 3-week intervals, alone or with assigned adjuvant (GM-CSF or imiquimod), for a total of 7 doses, and an option to continue vaccinating at 6 week intervals (without adjuvant). PBMCs and serum are collected at baseline and at each vaccination. Immune monitoring panels are run on peripheral whole blood to evaluate lymphocyte populations and their activation status. PBMCs from the baseline visit and week 12/13 are stimulated with DRibbles (vaccine and control) to measure vaccine-specific cytokine production. Patient serum from the baseline visit and week 12/13 is analyzed for antibody response to &#x0003e;9000 human proteins using ProtoArrays. Whole exome sequencing of tumors and normal tissue is performed when possible to evaluate antibody responses to mutations and altered peptide ligands. Nanostring and multispectral IHC are being used to evaluate tumor immune biomarkers when tissue is available.</p></sec><sec><title>Conclusions</title><p>The DPV-001 vaccine provides a source of broad-spectrum relevant antigens. Preliminary analyses of patients receiving the DPV-001 vaccine show effects on T cells and B cells with increased antibody responses at 12 or 13 weeks.</p><p>Clinical Trial Identifier: NCT01909752, Support: R44 CA121612-02A1.</p></sec><sec><title>Trial Registration</title><p>ClinicalTrials.gov identifier NCT01909752.</p></sec></body></article>